Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $57.50 Average PT from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $57.50.

A number of equities analysts recently weighed in on COLL shares. Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, March 20th.

Collegium Pharmaceutical Trading Down 1.0%

Shares of COLL stock opened at $34.07 on Friday. The stock has a 50-day simple moving average of $34.26 and a 200 day simple moving average of $41.54. Collegium Pharmaceutical has a fifty-two week low of $28.34 and a fifty-two week high of $50.79. The stock has a market capitalization of $1.10 billion, a P/E ratio of 16.70 and a beta of 0.76. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. During the same quarter last year, the business posted $1.49 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. On average, sell-side analysts expect that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP David Dieter sold 13,976 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the transaction, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. This trade represents a 15.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the transaction, the executive vice president owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 1.85% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Group One Trading LLC purchased a new stake in Collegium Pharmaceutical in the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares in the last quarter. Federated Hermes Inc. lifted its stake in Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in Collegium Pharmaceutical in the 4th quarter worth about $61,000. Finally, PNC Financial Services Group Inc. lifted its stake in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.